TXR-1007 / Aria Pharma - LARVOL DELTA

Aria Pharmaceuticals Presents Positive In Vivo Data Showing Two Novel Treatment Candidates Demonstrated Positive Efficacy and Tolerability in Idiopathic Pulmonary Fibrosis Compared to Standard of Care (PRNewswire) - "Aria Pharmaceuticals...today announced that two novel candidates for the potential treatment of idiopathic pulmonary fibrosis (IPF), TXR-1002 and TXR-1007, demonstrated significant efficacy and excellent tolerability in preclinical studies....'So far, the data for both novel candidates are very promising, and we're thrilled to present our findings at this year's IPF Summit'....In vivo efficacy with TXR-1002 and TXR-1007 was evaluated using a bleomycin-induced IPF mouse model. Data shows that both TXR-1002 and TXR-1007 decrease fibrosis and significantly decrease lung collagen staining..."

Preclinical • Idiopathic Pulmonary Fibrosis • Respiratory Diseases